Cancer Immunology Research

Table of Contents

AACR American Association for Cancer Research

March 2017 • Volume 5 • Issue 3

WHAT WE'RE READING

CANCER IMMUNOLOGY MINIATURES

PRIORITY BRIEF

RESEARCH ARTICLES

Table of Contents

CORRECTION

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Pancreatic cancer is a devastating disease that is refractory to most available treatment strategies. Nab-paclitaxel is a form of paclitaxel, a chemotherapeutic drug used against solid tumors, that is now a first-line treatment for pancreatic cancer. Nab-paclitaxel is actually a nanoparticle comprising paclitaxel bound to albumin. Cullis and colleagues examined the interaction of these particles with tumor-associated macrophages and found that the particles are ingested via macropinocytosis. This ingestion process influences the differentiation of the macrophages so that the number of antitumor macrophages is much increased. The fluorescence micrograph shows macrophages (blue nuclei) that have macropinocytosed nab-paclitaxel nanoparticles (green). Read more in the article by Cullis et al. in this issue of *Cancer Immunology Research*, starting on page 182. Micrograph is from Figure 1, and artwork is by Lewis Long.





Cancer Immunology Research

5 (3)

Cancer Immunol Res 2017;5:181-269.